Impact of Brokerage Rating on AMAG Pharmaceuticals, Inc.(AMAG)

Many AMAG Pharmaceuticals, Inc.(AMAG) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. AMAG Pharmaceuticals was Downgraded by Needham to Hold on Jan 11, 2017. AMAG Pharmaceuticals was Downgraded by Leerink Partners to Mkt Perform on Jan 10, 2017. AMAG Pharmaceuticals was Downgraded by Raymond James to Underperform on Jan 9, 2017.

Company has reported several Insider transactions to the SEC, on Oct 20, 2016, Julie Krop (SVP Clinical & Regulatory, CMO) sold 4,938 shares at 24.80 per share price.On Nov 10, 2015, John A. Fallon (director) purchased 3,230 shares at 31.20 per share price.On Oct 2, 2015, William K Heiden (CEO) sold 2,000 shares at 39.69 per share price.

AMAG Pharmaceuticals Last issued its quarterly earnings results on Feb 14, 2017. The company reported $-0.31 EPS for the quarter, missing the analyst consensus estimate by $ -2.17. Analyst had a consensus of $1.86. The company had revenue of $151.60 million for the quarter, compared to analysts expectations of $152.57 million. The companys revenue was up 39.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.12 EPS.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.56 by 9 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. 5 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) should head towards $32.56 per share according to 9 Analysts in consensus. However, if the road gets shaky, the stock may fall short to $20 per share. The higher price estimate target is at $45 according to the Analysts.

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) witnessed a decline in the market cap on Tuesday as its shares dropped 0.22% or 0.05 points. After the session commenced at $22, the stock reached the higher end at $23.1 while it hit a low of $21.8. With the volume soaring to 1,700,322 shares, the last trade was called at $22.65. The company has a 52-week high of $36.825. The company has a market cap of $775 million and there are 34,209,743 shares in outstanding. The 52-week low of the share price is $17.92.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease. Ferumoxytol, the companys key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients.Combidex?, the companys other product under development, is an investigational functional molecular imaging agent consisting of iron oxide nanoparticles for use in conjunction with magnetic resonance imaging to aid in the differentiation of cancerous from normal lymph nodes. In March 2005, the company received an approvable letter from the FDA with respect to Combidex, subject to certain conditions.

AMAG

For any feedback and suggestions contact author at Tracy.Brand@thefoundersdaily.com

Add Comment